Targeted Therapy
Approved for: NSCLC
Biomarker: EGFR
Dacomitinib (Vizimpro) is a FDA-approved treatment for Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR gene mutations.
